Acetate-free biofiltration for acute renal failure

Area of Science:

• Nephrology
• Intensive Care Medicine
• Renal Replacement Therapy

Background:

• Acetate-free biofiltration (AFB) is recognized for its benefits in chronic renal failure.
• Acute renal failure (ARF) management requires effective and safe dialysis techniques.
• Hemodynamic stability is crucial for critically ill patients with ARF.

Purpose of the Study:

• To prospectively compare the effectiveness and hemodynamic tolerance of AFB versus bicarbonate hemodialysis (BH) in ARF patients.
• To evaluate metabolic and acid-base balance correction in both groups.
• To assess the impact on heparin consumption, blood pressure variations, and overall patient outcomes.

Main Methods:

• Prospective study of 29 ARF patients in an intensive care unit.
• Random assignment to either AFB or BH using high-flux biocompatible membranes.
• Analysis of hemodynamic tolerance, acid-base and metabolic balance, heparin use, and blood pressure episodes.

Main Results:

• Both AFB and BH effectively corrected metabolic disorders and acid-base balance.
• Heparin consumption was higher in the AFB group, without increased hemorrhagic complications.
• AFB demonstrated a lower hypotensive risk during weight loss compared to BH (p < 0.05).
• No significant differences were observed in the number or degree of arterial pressure variations between groups.

Conclusions:

• Acetate-free biofiltration is an effective hemodialysis technique comparable to bicarbonate hemodialysis for ARF patients.
• AFB provides superior hemodynamic tolerance, especially during ultrafiltration, which is advantageous in intensive care.
• Further research comparing extended AFB sessions with continuous hemodiafiltration is warranted.